The new Dutch health insurance system and its implications for pharmaceutical innovation

International Journal of Pharmaceutical and Healthcare Marketing

Volumn 1, Issue 3, 2007, Pages 214-225

  Cohen, Joshua ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Health insurance; Innovation; Pharmaceuticals industry; The Netherlands

Indexed keywords

EID: 84877971751     PISSN: 17506123     EISSN: None     Source Type: Journal    
DOI: 10.1108/17506120710818229     Document Type: Article

References (36)

1. Acemoglu, D., Linn, J. (2003), "Market size in innovation: theory and evidence from the pharmaceutical industry", NBER Working Paper.
2. Carpenter, D., Chernew, M., Smith, D., Fendrick, A.M. (2003), "Approval times for new drugs: does the source of funding for FDA staff matter?", Health Affairs, Suppl Web Exclusives:W3-618-24 July-December.
3. CBO (2006), Research and Development in the Pharmaceutical Industry, United States Congressional Budget Office, October, available at: www.cbo.gov/ftpdocs/76xx/doc7615/10-02-DrugR-D.pdf.
4. Cohen, J., Faden, L., Predaris, S. (2007a), "Patient access to pharmaceuticals: an international comparison", European Journal of Health Economics, Vol. 8, No. 1, available at: http://dx.doi.org/10.1007/s10198-006-0028-z.
5. Cohen, J., Paquette, C., Cairns, C. (2007b), "Medicare formulary management: can lessons be drawn from Dutch experience with a national formulary?" in Drug Information Journal, Vol. 41, No. 2, pp. 257-72.
6. CPB (2004), "Vier lange termijn scenario's voor de Nederlandse overheid en gezondheidszorgsector ("Four long-term scenarios for the Dutch government and health care sector")", Central Plan Bureau.
7. CVZ (2004), "Procedure beoordeling intramurale geneesmiddelen ("Protocol on assessment of inpatient medications")", College Voor Zorgverzekeringen (Dutch board of insurers), available at: www.cvz.nl.
8. CVZ (2006), "Dutch guidelines for pharmacoeconomic research ("Dutch board of insurers")", College Voor Zorgverzekeringen, available at: www.ispor.org/PEguidelines/source/PE_guidelines_english_Netherlands.pdf.
9. CVZ (2007), "Monitor farmaceutische zorg ("Pharmaceutical care monitor")", College Voor Zorgverzekeringen (Dutch Board of Insurers), available at: www.cvz.nl.
10. Danzon, P.M., Wang, Y.R., Wang, L. (2005), "The impact of price regulation on the launch delay of new drugs - evidence from twenty-five major markets in the 1990s" in Health Economics, Vol. 14, No. 3, pp. 269-92.
11. Dutch Ministry of Health, Welfare, and Sport (2004), Reform of the Healthcare System of Curative Care and the General Law on Special Medical Expenses, Dutch Ministry of Health, Welfare, and Sport, The Hague, July.
12. (The) Economist (2007), "The federalist prescription: extending health care to the uncovered", The Economist, January 11.
13. Enthoven, A.C. (1993), "The history and principles of managed competition" in Health Affairs, Vol. 12, pp. 24-48, Supplement.
14. EPPOSI (2002), Timely Access to Innovative Medicines, European Program for Patients Organizations, Science and Industry, July, available at: www.epposi.org.
15. Garrison, L., Towse, A. (2003), "The drug budget silo mentality in Europe: an overview" in Value in Health, Vol. 6, No. 1, pp. 1-9.
16. Grol, R. (2006), Quality Development in Health Care in The Netherlands, Commonwealth Fund, available at: www.commonwealthfund.org/publications/publications_show.htm?doc_id = 362702 (accessed March).
17. Hockley, T. (2005), "Health care in the balance", Civitas, available at: www.civitas.org.uk/euseminars/MainReport.pdf.
18. Huttin, C. (1999), "Drug price divergence in Europe: regulatory aspects" in Health Affairs, Vol. 18, No. 3, pp. 245-9.
19. Hutton, J., Borowitz, M., Oleksy, I., Luce, B.R. (1994), "The pharmaceutical industry and health reform: lessons from Europe" in Health Affairs, Vol. 13, No. 3, pp. 98-111.
20. International Trade Administration (2004), "Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, research and development, and innovation", International Trade Administration, US Department of Commerce, available at: www.trade.gov/td/health/DrugPricingStudy.pdf.
21. Kern, S., Enzing, C. (2002), "The Dutch biotechnology innovation system: an inventory and assessment of the major developments since 1994", available at: www.sussex.ac.uk/spru/documents/netherlandscountryreport.pdf.
22. Koopmanschap, M.A., Rutten, F.F. (2003), "The drug budget silo mentality: the Dutch case" in Value in Health, Vol. 6, No. 1, pp. 46-51.
23. Lanjouw, J. (2005), "Patents, price controls and access to new drugs: how policy affects global market entry", working paper, Agricultural and Resource Economics Department, University of California, Berkeley, January.
24. Maarse, H. (2006), "The privatization of health care in Europe: an eight-country analysis" in Journal of Health Politics, Policy & Law, Vol. 31, No. 5, pp. 981-1014.
25. Maarse, H., Bartholomee, Y. (2007), "A public-private analysis of the new Dutch health insurance system" in European Journal of Health Economics, Vol. 8, No. 1, pp. 77-82.
26. Maynard, A., Bloor, K. (2003), "Dilemmas in regulation of the market for pharmaceuticals" in Health Affairs, Vol. 22, No. 3, pp. 31-41.
27. Milne, C-P. (2002), "The single controlled trial: industry survey indicates that implementation is still a work in progress" in Drug Information Journal, Vol. 36, No. 2, pp. 291-302.
28. OECD (2004), Health Ministerial Meeting, Organization for Economic Cooperation and Development, Paris, Speech by Minister Hans Hoogervorst, May 13.
29. OECD (2005), OECD Health Data 2005: How Does the Netherlands Compare?, Organization for Economic Cooperation and Development, Paris, available at: www.oecd.org/dataoecd/15/26/34970210.pdf.
30. Pronk, M.H., Bonsel, G.J., van der Kuy, A. (2002), "De budgetbeheersende functie van het geneesmiddelenvergoedingssysteem, 10 jaar GV ("The budget control function of the Drug Reimbursement System")" in Nederlands Tijdschrift voor Geneeskunde, Vol. 146, No. 37, pp. 1729-33.
31. RVZ (2006), "Zinnige en duurzame zorg. ("Useful and durable health care")", Raad voor de Volksgezondheid en Zorg, available at: www.rvz.net/data/download/advies_Zinnige_zorg.pdf.
32. Sheldon, T. (1998), "Dutch coalition tackles waiting lists" in BMJ, pp. 316-955, March 28.
33. Tapay, N., Colombo, F. (2004), "Private health insurance in The Netherlands: a case study", OECD Health Working Papers.
34. Van der Wilk, E.A., Achterberg, P.W., MacGillavry, E., Zwakhals, L., Van Linden, F. (2004), How Do We Do? Health in the EU from a Dutch Perspective, Ministry of Health, Welfare, and Sport, The Hague.
35. Varkevisser, M., van der Geest, S. (2006), "Farmaceutische zorg in de basisverzekering: vrijheden en verplichtingen voor zorgverzekeraars ("Pharmaceutical benefits management: choices and limits for insurers")", Erasmus Competition and Regulation Institute, Erasmus University, Amsterdam.
36. Wilking, N., Jönsson, B. (2006), "A pan-European comparison of patient access to cancer medications", Stockholm: Karolinska Institute, working paper.